Sagent Pharmaceuticals, Inc. Will Spend $30 Million To Expand China Plant

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

March 18, 2014 -- Sagent Pharmaceuticals will invest $30 million to build a second production line at its China production plant. At full capacity, the Chengdu facility will be able to supply 25% of its annual product needs. In general, Sagent uses partners to produce its portfolio of injectables products, but it spent $25 million last year to buy out its China JV partner and bring the Chengdu operation entirely in-house, the only production facility Sagent owns. More details....

Stock Symbol: (NSDQ: SGNT)

Help employers find you! Check out all the jobs and post your resume.

Back to news